ABSTRACT
PURPOSE: The distinction between active inflammation and fibrosis of the bowel wall is essential for therapeutic decisions in stricturing Crohn's disease. We aimed to assess whether real-time elastography (RTE) with strain ratio measurement could be useful in differentiating fibrotic from inflamed bowel strictures and to evaluate the possible relationship between US techniques and the histology of the stenotic bowel wall. MATERIALS AND METHODS: Bowel ultrasonography (including RTE, color-Doppler and CEUS examination) was prospectively evaluated in 26 patients with symptomatic stricturing Crohn's disease, before surgery. RTE was adopted to evaluate bowel stiffness: five loops of 20 RTE frames were recorded for each stenotic segment and the mean strain ratio (MSR) was obtained. Histology scoring systems both for inflammation and fibrosis were established for surgical specimens. RESULTS: No significant correlation was found between MSR and fibrosis score (P = 0.877). Color-Doppler score was significantly related to gut wall and submucosal thicknesses (P = 0.006 and P = 0.032, respectively). There was no significant correlation between the number of vessels counted at histology and color-Doppler and CEUS examinations (P = 0.170 and P = 0.302, respectively). CONCLUSION: MSR detection was not able to distinguish fibrotic from inflammatory tissue in our selected population. This result could be influenced by the presence of the superimposed inflammation. Larger cohort of patients, further analysis with shear wave elastography, and validated histopathology classification systems for fibrosis and inflammation are necessary to assess if intestinal fibrosis could be reliably detected on the basis of bowel elastic properties.
Subject(s)
Crohn Disease/diagnostic imaging , Elasticity Imaging Techniques , Fibrosis/diagnostic imaging , Inflammation/diagnostic imaging , Intestines/diagnostic imaging , Adult , Crohn Disease/pathology , Crohn Disease/physiopathology , Crohn Disease/surgery , Elasticity Imaging Techniques/methods , Female , Fibrosis/pathology , Fibrosis/physiopathology , Fibrosis/surgery , Follow-Up Studies , Humans , Inflammation/pathology , Inflammation/physiopathology , Inflammation/surgery , Intestinal Obstruction/diagnostic imaging , Intestinal Obstruction/pathology , Intestinal Obstruction/physiopathology , Intestinal Obstruction/surgery , Intestines/pathology , Intestines/surgery , Male , Middle Aged , Prospective Studies , Severity of Illness Index , Young AdultABSTRACT
Outstanding progress regarding the pathophysiology of Crohn's disease (CD) has led to the development of innovative therapeutic concepts. Numerous controlled trials have been performed in CD. This review concentrates on the results of randomized, placebo-controlled trials, and meta-analyses when available, that provide the highest degree of evidence. Current guidelines on the management of CD recommend a step-up approach to treatment involving the addition of more powerful therapies as the severity of disease and refractoriness to therapy increase. The advent of biological drugs has opened new therapeutic horizons for treating CD, modifying the treatment goals. However, the large majority of patients with CD will be managed through conventional therapy, even if they are a prelude to biological therapy.